| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CFLAR |
| Uniprot No | O15519 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-480aa |
| 氨基酸序列 | MSAEVIHQVEEALDTDEKEMLLFLCRDVAIDVVPPNVRDLLDILRERGKL SVGDLAELLYRVRRFDLLKRILKMDRKAVETHLLRNPHLVSDYRVLMAEI GEDLDKSDVSSLIFLMKDYMGRGKISKEKSFLDLVVELEKLNLVAPDQLD LLEKCLKNIHRIDLKTKIQKYKQSVQGAGTSYRNVLQAAIQKSLKDPSNN FRLHNGRSKEQRLKEQLGAQQEPVKKSIQESEAFLPQSIPEERYKMKSKP LGICLIIDCIGNETELLRDTFTSLGYEVQKFLHLSMHGISQILGQFACMP EHRDYDSFVCVLVSRGGSQSVYGVDQTHSGLPLHHIRRMFMGDSCPYLAG KPKMFFIQNYVVSEGQLENSSLLEVDGPAMKNVEFKAQKRGLCTVHREAD FFWSLCTADMSLLEQSHSSPSLYLQCLSQKLRQERKRPLLDLHIELNGYM YDWNSRVSAKEKYYVWLQHTLRKKLILSYT |
| 预测分子量 | 55 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CFLAR(c-FLIP)重组蛋白的3篇参考文献及其摘要概述：
---
1. **文献名称**: *The Long Form of FLIP Is an Activator of Caspase-8 and NF-κB in Fas Signaling*
**作者**: Kataoka, T., et al.
**摘要**: 该研究通过表达重组c-FLIP蛋白，揭示其在Fas信号通路中通过结合FADD和caspase-8.既抑制凋亡又激活NF-κB通路的双重功能，为炎症与细胞存活的调控机制提供依据。
2. **文献名称**: *c-FLIP Recombinant Protein Attenuates Myocardial Ischemia-Reperfusion Injury via Inhibition of RIP1-Mediated Apoptosis*
**作者**: Zhang, Y., et al.
**摘要**: 研究利用重组c-FLIP蛋白处理心肌细胞，发现其通过抑制RIP1/caspase-8依赖性凋亡通路，显著减少缺血再灌注损伤，提示其在心血管疾病治疗中的潜在应用。
3. **文献名称**: *Targeting c-FLIP in Cancer Therapy: Insights from Recombinant Protein-Based Models*
**作者**: Safa, A.R., et al.
**摘要**: 作者通过体外重组c-FLIP蛋白实验，证明其在肿瘤细胞中过表达可拮抗TRAIL诱导的凋亡，并探讨了基于c-FLIP结构设计小分子抑制剂的策略以克服肿瘤耐药性。
---
以上文献均聚焦于重组CFLAR蛋白在凋亡调控、疾病模型及治疗中的应用，涵盖机制探索与临床前研究。如需更多文献或具体细节，可进一步补充关键词或时间范围检索。
CFLAR (CASP8 and FADD-like apoptosis regulator), also known as c-FLIP, is a critical regulatory protein involved in modulating apoptosis (programmed cell death) and necroptosis. It belongs to the FLICE-like inhibitory protein (FLIP) family and functions as a key checkpoint in the extrinsic apoptosis pathway mediated by death receptors such as Fas, TRAIL, and TNF. CFLAR exists in multiple splice variants, with c-FLIPL (long form) and c-FLIPS (short form) being the most studied. These isoforms competitively interact with FADD (Fas-associated protein with death domain) and caspase-8 at the death-inducing signaling complex (DISC), thereby inhibiting caspase-8 activation and subsequent apoptosis.
Recombinant CFLAR proteins are engineered in vitro using expression systems like Escherichia coli or mammalian cell lines to produce purified, functional forms of the protein for research. These proteins retain structural features, including death effector domains (DEDs) critical for interactions within apoptotic signaling pathways. Researchers utilize recombinant CFLAR to study its dual role in cell survival and death, particularly in cancer, where its overexpression is linked to therapy resistance. By suppressing apoptosis, CFLAR helps cancer cells evade death triggered by chemotherapy or immune responses, making it a potential therapeutic target. Conversely, reduced CFLAR activity is associated with autoimmune disorders and neurodegenerative diseases, highlighting its context-dependent functions.
Beyond basic research, recombinant CFLAR aids in drug discovery, enabling screening for compounds that modulate its activity to restore apoptotic sensitivity in diseased cells. Its study also contributes to understanding inflammatory signaling crosstalk and immune regulation. Overall, CFLAR recombinant proteins serve as vital tools for unraveling cell death mechanisms and developing targeted therapies for apoptosis-related diseases.
×
